Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19
In parallel to the publication of revised guidance from the National Institute for Health and Care Excellence (NICE), the previously published UK interim position statement covering inhaled budesonide as a treatment option for individuals with COVID infection has been withdrawn.
Inhaled budesonide should no longer be considered as a treatment for COVID-19 infection other than within the context of a clinical trial. People already using budesonide for conditions other than COVID-19 should continue treatment if they test positive for COVID-19.
Further information and actions can be found in the alert.